January 24, 2007
Following a rash of approvable letters at the end of 2006 for a number of products, Wyeth Pharmaceuticals announced that it has received an FDA approvable letter on January 22 for Pristiq (TM) – desvenlafaxine succinate – a serotonin-norepinephrine reuptake … Continue reading →
A total of seven companies received Warning Letters during the last quarter, meaning that one-third of the year’s letters came in the final three months of the year. What we saw is a mix of large and small companies, with … Continue reading →